Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data

Human epidermal growth factor receptor type 2 (HER2) is a relevant and effective target in breast cancer. The development of monoclonal antibodies against HER2 has revolutionized the treatment of HER2-positive breast cancer. The humanized monoclonal antibody, trastuzumab, was the first in its class...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagosky, Megan, Tan, Antoinette R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213954/
https://www.ncbi.nlm.nih.gov/pubmed/34163239
http://dx.doi.org/10.2147/BCTT.S176514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213954/
https://www.ncbi.nlm.nih.gov/pubmed/34163239
http://dx.doi.org/10.2147/BCTT.S176514

Ejemplares similares